search
Back to results

Orthognathic Surgery and Postoperative Antibiotic Use

Primary Purpose

Dentofacial Deformity

Status
Unknown status
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Cefazolin, Cephalexin, Clindamycin
Sponsored by
Atlantic Center for Oral and Maxillofacial Surgery
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Dentofacial Deformity

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • over 16 years old undergoing orthognathic surgery

Exclusion Criteria:

  • Use of antibiotics in last 2 weeks, active oral or odontogenic infection, significant medical condition, immunocompromised

Sites / Locations

  • Victoria General HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Cefazolin, Cephalexin, Clindamycin

cefazolin, clindamycin, placebo

Arm Description

Group will be receiving 1 day of IV cefazolin or clindamycin followed by 2 days of oral cephalexin or clindamycin Clindamycin will be used in patients with allergy

Group will receive 1 day IV cefazolin, or clindamycin followed by 2 days of oral placebo clindamycin will be used if patient has allergy

Outcomes

Primary Outcome Measures

Rate of infection
Investigation of the incidence of post operative infection following surgery in each of the two groups

Secondary Outcome Measures

Side effect from antibiotic use
investigation of the incidence of side effects from an extended antibiotic regimen

Full Information

First Posted
March 29, 2013
Last Updated
January 12, 2015
Sponsor
Atlantic Center for Oral and Maxillofacial Surgery
search

1. Study Identification

Unique Protocol Identification Number
NCT01823523
Brief Title
Orthognathic Surgery and Postoperative Antibiotic Use
Official Title
Orthognathic Surgery and Postoperative Antibiotic Use
Study Type
Interventional

2. Study Status

Record Verification Date
January 2015
Overall Recruitment Status
Unknown status
Study Start Date
June 2013 (undefined)
Primary Completion Date
October 2015 (Anticipated)
Study Completion Date
October 2015 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Atlantic Center for Oral and Maxillofacial Surgery

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Currently there is debate in the literature as to the recommended length of postoperative antibiotics in patients undergoing orthognathic surgery. The investigators plan to investigate using a randomized controlled trial the comparison between a 1 day and 3 day regimen of antibiotics and the effects on post operative infection.
Detailed Description
Capital Health Research Ethics Board Orthognathic Surgery and Postoperative Antibiotic Use Protocol Background, Rationale and Statement of Research Question(s): Surgical site infection is a potential problem with any surgical procedure. Surgical procedures done through the oral cavity are at a higher risk due to the presence of bacterial pathogens. Orthognathic surgery, involves incising through oral mucosa and creating osteotomies in underlying bony structures. Of the potential complications that can arise from this surgery, post operative infection (POI) is the most common. POI can have a significant impact on surgical outcomes and are associated with an increased cost to the health care system. The literature is quite clear on the benefits of presurgical prophylactic antibiotics in reducing the rate of post operative surgical site infections.1 Currently there is conflicting literature as to the recommended length patients should receive antibiotics during the postoperative course, and the majority of studies have small sample sizes.2,3 Orthognathic surgery is considered a clean-contaminated surgery with a suspected POI rate of 10-15%.2 In 1999 Bentley et. al conducted a randomized control trial comparing 1day vs 5day regimen of antibiotics following orthognathic surgery.4 This trial was stopped due to the drastic difference seen between the two groups, 6.7% in the 5 day course compared with 60% seen in the 1 day group.4 This data varies greatly from the rates of infection that the investigators have seen in their department using a 1 day course of antibiotics. Chow et al. in 2007 did a retrospective chart review of complications seen in orthognathic surgery. They found the rate of infection was significantly decreased by continuing antibiotics in the post operative course when compared to using only one prophylactic dose. They found the infection rates to be 17.3% with a single preoperative IV dose, 5.1% with a pre-operative dose and 2 days post-operative, and 7.7% with a pre-operative dose and 3 days of post-operative antibiotics.5 They also found no significant difference in rates of infection comparing 2 days and up to 14 days.5 A meta-analysis by Danda et al. in 2011 found that a regimen consisting of a single dose of preoperative antibiotics followed with an extended term postoperatively is the most effective in decreasing surgical site infections. They found the incidence decreased by 3.2 times, with the greatest effect noted with administration for 2 days.2 Even in this meta-analysis the average number of patients in each of the 8 studies was 67, with the total number of patients included being 532.2 This shows the need for randomized controlled studies with large sample sizes in order to determine the best antimicrobial regimen for these patients. The majority of studies investigating the rates of infection in orthognathic surgery use penicillin as the antibiotic of choice due to its spectrum of coverage for oral microbes and it is reasonably tolerated by patients.2,4-8 In the investigators department cefazolin is the antibiotic of choice and lower rates of infection have been observed compared to penicillin. The investigators suspect the lower rates of infection with cefazolin is due to the increased gram negative coverage and better resistance to beta lactamases. This has influenced the investigators decision to use first generation cephalosporins instead of penicillin as first line antimicrobials. In patients allergic to penicillin, clindamycin is used. The criteria for diagnosis of infection will follow the CDC guidelines for SSI. The primary outcome is to determine if there is any benefit to extending antimicrobials in the postoperative course following orthognathic surgery. Secondary outcomes include comparing the rates of infection between cefazolin/cephalexin groups and the clindamycin groups, and the rate of infection with different surgical procedures. Currently at the CDHA the standard perioperative antimicrobial regimen for orthognathic surgery patients is one preoperative prophylactic dose of 2g of IV cefazolin followed by 1g IV every 8 hrs for 3 doses. Patients with an allergy to penicillin receive one preoperative prophylactic dose of IV Clindamycin 600mg, followed by 600mg IV every 8 hrs for 3 doses. The investigators plan to conduct a double blind randomized controlled trial comparing the effect of a single day of post operative antibiotics with an extended 3 day course of antimicrobials on the infection rate. Both groups will receive an IV prophylactic dose followed by 3 IV doses postoperatively. Group 1 will then receive PO antibiotics for 2 subsequent days following IV treatment, and group 2 will receive a PO placebo. A placebo will be used in order to blind the two groups so that the patient, surgeon and investigators are not aware of which patients are receiving the extended regimen of antibiotics. This will avoid potential bias in the patient report of symptoms or side effects, and the surgeon's bias in diagnosis of surgical site infection. Subject Selection: All patients over the age of 16 years undergoing orthognathic surgery at the QEII VG hospital are eligible to participate in the study. All surgeons operating at the VG site have been asked to include their patients in this study. These include patients undergoing either isolated Lefort I osteotomy, bilateral sagittal split osteotomies, functional genioplasties, or any combination of the three procedures. Wisdom teeth, if present, will also be extracted at the time of the surgery. Exclusion criteria include use of antibiotics in the past 2 weeks, active oral or odontogenic infection, significant medical condition, or if the patient is immunocompromised. All patients will have history and physical examination, CBC, INR/PTT, electrolytes as well as a radiographic evaluation prior to surgery. A power analysis was done to determine the required patient sample size for this study. This was done using a 5% change in infection as clinically significant and type I error of 0.05 with 0.90 power. The sample size required would be 397 patients. The investigators would like to enroll as many as possible over the next 2 years and anticipate to enroll approximately 500 patients. Study enrollment will finish in 2 years time from starting date, unless required sample size has not been met at which time it may be decided to extend length. Research Plan: All patients enrolled in the study will receive the standard preoperative IV prophylactic antibiotic, followed by 3 IV doses postoperatively. The patients will be randomly allocated to either the placebo or the antibiotic group at their presurgical assessment appointment. This allocation will be done by a clinical nurse, patients will be given a study patient number and handed a envelope from a folder that has been mixed sufficiently, inside this envelope will be a paper with an A or B denoting to the Shoppers Drug Mart pharmacy on the main floor of the VG hospital to dispense the according bottle they are to receive. This will be recorded beside their study number, and not be unblinded until the study is concluded. Blinding is important to avoid bias in assessment of infection by the surgeons, and to avoid bias in reporting of symptoms of either infection or side effects from the antibiotics. Following the completion of the IV antibiotic regimen, group 1 will receive oral cephalexin or clindamycin four times per day for 2 days and group 2 will receive a placebo four times per day for 2 days. All patients will also be sent home with specific oral hygiene instructions in addition to chlorhexidine 0.12% rinse to be used for 2 weeks postoperatively. Patients will be assessed for signs of infection and recovery progress daily during hospital stay and during regular recall visits at 2 weeks and 4 weeks following discharge. There is no additional time requirements or cost to the patient by participating in this study. The diagnosis of infection will be made according to the CDC criteria of surgical site infection which include: purulent drainage, wound culture for known pathogen, at least one of signs or symptoms of infection (pain, tenderness, localized swelling, redness or heat)1. The patient may withdrawl from the study at any time. A patient may be removed from the study if there is a significant change in the patients medical condition. An interm review of the rates of infection will be done and if the data demonstrates an increase risk to patients participating in study, the study will be stopped and unblinded. All adverse events, serious adverse events, adverse drug reations will be reported to the Oral Maxillofacial Surgery Department and the patient will be assessed by the resident or attending surgeon. Analysis of Data All of the data will be organized and pooled according to each specific group. Following the study the blinding will be undone, and the primary outcome investigating the rate of infection will be analyzed in each of the four groups, 1 day cefazolin, 3 day cefazolin/cephalexin, 1 day clindamycin, 3 day clindamycin. Each of the 1 day groups will be compared and the 3 day groups in order to determine if the length of time on antibiotic has an effect on the rate of infection. Then the 1 day group and 3 day groups will be compared for the different type of antibiotic to see if the type of antibiotic has bearing on the length required. These comparisons will be done using a chi squared formula to look for statistical significance. This analysis will also be used to compare rates of infection between the type of surgical procedures done. Each of the groups will also be analyzed for possible confounding factors including time of surgery, age, sex, and oral hygiene status. Confidentiality All data will be kept secure by the research team by storing it in a locked office filing cabinet, or on a password protected file on the secured hospital network. Only the investigators, and research nurse will have access to this data. Following the study, the data will be kept in a locked cabinet for at least 25 years as required by law. Harms As all patients will receive the standard current protocol used at the investigators center, with the test group receiving an addition 2 days of antibiotics. The risks associated with participation in the study are those seen from prolonged antibiotic use. These include allergic reactions ranging from rash to anaphylaxis, toxic reactions to kidney, liver, gastrointestinal and secondary infections from candida or resistant pathogens. If anaphylaxis occurs normal protocol will be followed for treatment and monitoring. In the event of other adverse events from the antibiotic it will be stopped and any secondary infections will be treated appropriately. In the case of post operative infection this will be treated with a 10 day course of appropriate antibiotics. Benefits Overall the benefit of this study is to determine the ideal length of postoperative antibiotics in preventing post operative surgical site infections in patients undergoing orthognathic surgery. The group receiving an extended course of antibiotics potentially may have a lower rate of infection. Conversely, the placebo group may have the same rate of infection and avoid potential side effects of extended antibiotic treatment. Disclosure of Any Financial Compensation There will be no monetary compensation for participation in this study. Either the antibiotic or the placebo will be provided to the patient at no cost. References National Center for Infectious Diseases, Mangram AJ, Horan TC, Pearson ML, et. al. Guideline for Prevention of Surgical Site Infection, 1999. Infection Control and Hospital Epidemiology, 20:4:247- 278, 1999 Danda AK, Ravi P. Effectiveness of Postoperative Antibiotics in Orthognathic Surgery: A Meta-Analysis. J Oral Maxillofacial Surgery 69:2650-2656,2011 Tan SK, Lo J, Zwahlen RA. Perioperative Antibiotic Prophylaxis in Orthognathic Surgery: A Systematic Review and Meta-Analysis of Clinical Trials. Surg Oral Med Oral Pathology Oral Radiology Endodontics 112:19-27, 2011 Bentley KC, Head TW, Aiello GA. Antibiotic Prophylaxis in Orthognathic Surgery: A 1-Day Versus 5-Day Regimen. J Oral Maxillofacial Surgery 57:226-230.1999 Chow LK, Singh B, et al. Prevalence of Postoperative Complications After Orthognathic Surgery: A 15year Review. J Oral Maxillofacial Surgery 65:984-992, 2007 Ruggles JE, Hann JR, Antibiotic Prophylaxis in Intraoral Orthognathic Surgery. J Oral Maxillofacial Surgery 42:797-801, 1984. Fridrich KL, Partnoy BE, Zeitler DL. Prospective analysis of Antibiotic Prophylaxis for Orthognathic Surgery. International Journal Adult Orthodontic and Orthognathic Surgery 9:129-131, 1994 Jansisyanont P, Sessirisombat S, Sastravaha P, Bamroong P, Antibiotic Prophylaxis for Orthognathic Surgery: A Prospective, Comparative, Randomized Study between Amoxicillin-Clavulanic Acid and Penicillin. J Med Association Thailand 11: 1726-31, 2008. Advertisements No advertisements will be used for enrollment in this study. Additional Considerations Funding has been provided by the Canadian Association of Oral and Maxillofacial Surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dentofacial Deformity

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cefazolin, Cephalexin, Clindamycin
Arm Type
Active Comparator
Arm Description
Group will be receiving 1 day of IV cefazolin or clindamycin followed by 2 days of oral cephalexin or clindamycin Clindamycin will be used in patients with allergy
Arm Title
cefazolin, clindamycin, placebo
Arm Type
Placebo Comparator
Arm Description
Group will receive 1 day IV cefazolin, or clindamycin followed by 2 days of oral placebo clindamycin will be used if patient has allergy
Intervention Type
Drug
Intervention Name(s)
Cefazolin, Cephalexin, Clindamycin
Other Intervention Name(s)
Ancef, Keflex, Dalacin C
Primary Outcome Measure Information:
Title
Rate of infection
Description
Investigation of the incidence of post operative infection following surgery in each of the two groups
Time Frame
4 weeks following surgery
Secondary Outcome Measure Information:
Title
Side effect from antibiotic use
Description
investigation of the incidence of side effects from an extended antibiotic regimen
Time Frame
4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: over 16 years old undergoing orthognathic surgery Exclusion Criteria: Use of antibiotics in last 2 weeks, active oral or odontogenic infection, significant medical condition, immunocompromised
Facility Information:
Facility Name
Victoria General Hospital
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3H 1W2
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Clayton Davis, DDS
Phone
902-473-2070
Email
cmd@dal.ca

12. IPD Sharing Statement

Citations:
PubMed Identifier
10196487
Citation
Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999 Apr;27(2):97-132; quiz 133-4; discussion 96.
Results Reference
background
PubMed Identifier
21549486
Citation
Danda AK, Ravi P. Effectiveness of postoperative antibiotics in orthognathic surgery: a meta-analysis. J Oral Maxillofac Surg. 2011 Oct;69(10):2650-6. doi: 10.1016/j.joms.2011.02.060. Epub 2011 May 6.
Results Reference
background
PubMed Identifier
21168350
Citation
Tan SK, Lo J, Zwahlen RA. Perioperative antibiotic prophylaxis in orthognathic surgery: a systematic review and meta-analysis of clinical trials. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Jul;112(1):19-27. doi: 10.1016/j.tripleo.2010.07.015. Epub 2010 Dec 17.
Results Reference
background
PubMed Identifier
10077192
Citation
Bentley KC, Head TW, Aiello GA. Antibiotic prophylaxis in orthognathic surgery: a 1-day versus 5-day regimen. J Oral Maxillofac Surg. 1999 Mar;57(3):226-30; discussion 230-2. doi: 10.1016/s0278-2391(99)90664-x.
Results Reference
background
PubMed Identifier
17448852
Citation
Chow LK, Singh B, Chiu WK, Samman N. Prevalence of postoperative complications after orthognathic surgery: a 15-year review. J Oral Maxillofac Surg. 2007 May;65(5):984-92. doi: 10.1016/j.joms.2006.07.006.
Results Reference
background
PubMed Identifier
6594473
Citation
Ruggles JE, Hann JR. Antibiotic prophylaxis in intraoral orthognathic surgery. J Oral Maxillofac Surg. 1984 Dec;42(12):797-801. doi: 10.1016/0278-2391(84)90348-3.
Results Reference
background
PubMed Identifier
7989814
Citation
Fridrich KL, Partnoy BE, Zeitler DL. Prospective analysis of antibiotic prophylaxis for orthognathic surgery. Int J Adult Orthodon Orthognath Surg. 1994;9(2):129-31.
Results Reference
background
PubMed Identifier
19127796
Citation
Jansisyanont P, Sessirisombat S, Sastravaha P, Bamroong P. Antibiotic prophylaxis for orthognathic surgery: a prospective, comparative, randomized study between amoxicillin-clavulanic acid and penicillin. J Med Assoc Thai. 2008 Nov;91(11):1726-31.
Results Reference
background

Learn more about this trial

Orthognathic Surgery and Postoperative Antibiotic Use

We'll reach out to this number within 24 hrs